JP2010529038A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529038A5
JP2010529038A5 JP2010510505A JP2010510505A JP2010529038A5 JP 2010529038 A5 JP2010529038 A5 JP 2010529038A5 JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010529038 A5 JP2010529038 A5 JP 2010529038A5
Authority
JP
Japan
Prior art keywords
patients
imatinib
leukemia
treatment
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010510505A
Other languages
English (en)
Japanese (ja)
Other versions
JP5888853B2 (ja
JP2010529038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/065215 external-priority patent/WO2008150957A2/en
Publication of JP2010529038A publication Critical patent/JP2010529038A/ja
Publication of JP2010529038A5 publication Critical patent/JP2010529038A5/ja
Application granted granted Critical
Publication of JP5888853B2 publication Critical patent/JP5888853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010510505A 2007-06-01 2008-05-30 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 Active JP5888853B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014016309A Division JP2014111629A (ja) 2007-06-01 2014-01-31 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2015229117A Division JP2016074700A (ja) 2007-06-01 2015-11-24 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Publications (3)

Publication Number Publication Date
JP2010529038A JP2010529038A (ja) 2010-08-26
JP2010529038A5 true JP2010529038A5 (cg-RX-API-DMAC7.html) 2016-01-14
JP5888853B2 JP5888853B2 (ja) 2016-03-22

Family

ID=39639071

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510505A Active JP5888853B2 (ja) 2007-06-01 2008-05-30 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2014016309A Pending JP2014111629A (ja) 2007-06-01 2014-01-31 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2015229117A Pending JP2016074700A (ja) 2007-06-01 2015-11-24 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014016309A Pending JP2014111629A (ja) 2007-06-01 2014-01-31 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2015229117A Pending JP2016074700A (ja) 2007-06-01 2015-11-24 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Country Status (23)

Country Link
US (1) US11103497B2 (cg-RX-API-DMAC7.html)
EP (4) EP2777704A3 (cg-RX-API-DMAC7.html)
JP (3) JP5888853B2 (cg-RX-API-DMAC7.html)
KR (1) KR101493543B1 (cg-RX-API-DMAC7.html)
CN (1) CN101686973B (cg-RX-API-DMAC7.html)
AU (1) AU2008260070B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812355A2 (cg-RX-API-DMAC7.html)
CA (3) CA2688467C (cg-RX-API-DMAC7.html)
CL (1) CL2008001577A1 (cg-RX-API-DMAC7.html)
CY (2) CY1115251T1 (cg-RX-API-DMAC7.html)
DK (2) DK2478905T3 (cg-RX-API-DMAC7.html)
ES (2) ES2881391T3 (cg-RX-API-DMAC7.html)
HU (1) HUE055524T2 (cg-RX-API-DMAC7.html)
IL (1) IL202407A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013069A (cg-RX-API-DMAC7.html)
PA (1) PA8782301A1 (cg-RX-API-DMAC7.html)
PL (2) PL3002009T3 (cg-RX-API-DMAC7.html)
PT (2) PT3002009T (cg-RX-API-DMAC7.html)
RU (1) RU2464026C2 (cg-RX-API-DMAC7.html)
SI (2) SI3002009T1 (cg-RX-API-DMAC7.html)
TW (1) TW200908982A (cg-RX-API-DMAC7.html)
WO (1) WO2008150957A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908480B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
EP4746884A2 (en) * 2023-07-21 2026-05-27 Icahn School of Medicine at Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP2341133A1 (en) 2001-10-05 2011-07-06 Novartis AG Mutated Abl kinase domains
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
CA2543163A1 (en) 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
AU2006270187A1 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
WO2007056177A2 (en) * 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Similar Documents

Publication Publication Date Title
Jabbour et al. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
An et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review
JP2009537552A5 (cg-RX-API-DMAC7.html)
JP2016521266A5 (cg-RX-API-DMAC7.html)
MX2009013781A (es) Inhibidores de cinasa de proteina y metodos para el uso de los mismos.
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
JP2009513660A5 (cg-RX-API-DMAC7.html)
IL184673A0 (en) COMPOUNDS POSSESSING B-Raf INHIBITORY ACTIVITY, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR PRODUCING AN ANTI-CANCER EFFECT IN WARM-BLOODED ANIMALS
ATE494899T1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
MX272108B (es) Heterociclos sustituidos.
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
JP2022554258A5 (cg-RX-API-DMAC7.html)
PL3002009T3 (pl) Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib
WO2023245156A3 (en) Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
WO2007120726A3 (en) Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
JP2005530735A5 (cg-RX-API-DMAC7.html)
JP2018502089A5 (cg-RX-API-DMAC7.html)
CN109689657A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
JP2010526884A5 (cg-RX-API-DMAC7.html)
Rej et al. In this correspondence, preliminary data in 100 lithium users found that urine osmolality correlated with chronic kidney disease, diabetes mellitus, and hypothyroidism. We hypothesize that GSK-3β inhibition is a potential mechanism for lithium-associated medical illness
RU2005134430A (ru) Способ базисного лечения хронического вирусного гепатита c
CN116075504A (zh) 化合物的结晶形式
Üsküdar Teke et al. Pleural effusion: a rare side effect of nilotinib—a case report